These four top dividend stocks offer dependable passive income streams and solid total return, and they are too cheap to ...

Here are three dividend stocks that retirees can buy with confidence as they offer recurring, dependable payouts and a degree ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the ...

Viatris has faced volatility since its 2020 formation but is now in Phase 2 of its transformation. Learn why VTRS stock could ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

Amgen's biosimilar ambition is targeting several ... especially while its shares remain down. Pfizer's dividend is safer than it looks David Jagielski(Pfizer): A high-yielding stock that could ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... concerns include competition from generic drugs and biosimilars and the looming patent cliff, with over $300 billion ...